IRIDEX

IRIDEX Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of IRIDEX (IRIX) as of Nov 12, 2026 is 47.67 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 81.76 % — a change of -41.70% (lower).

Cash Conversion

47.67 %

YoY

-41.70%

Last updated:

Cash Conversion Rate (OCF/Net Income) of IRIDEX is 2025 47.67 % . Cash Conversion Rate (OCF/Net Income) of IRIDEX was 2024 81.76 % . It decreases by -41.70% lower compared to the previous year.

The IRIDEX Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
78.24 USD
Jan 1, 2019
89.79 USD
Jan 1, 2020
51.15 USD
Jan 1, 2021
-157.26 USD
Jan 1, 2022
126.13 USD
Jan 1, 2023
70.48 USD
Jan 1, 2024
81.76 USD
Jan 1, 2025
47.67 USD
The IRIDEX Cash Conversion history
YEARCash ConversionYoY
47.67 %-41.70%
81.76 %+16.01%
70.48 %-44.12%
126.13 %-180.20%
-157.26 %-407.48%
51.15 %-43.04%
89.79 %+14.76%
78.24 %+182.39%
27.71 %+2,153.66%
1.23 %-100.98%
-125.11 %-412.86%
39.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IRIDEX Stock analysis

What does IRIDEX do? IRIDEX Corp is a global medical technology company that specializes in the development, manufacturing, marketing, and distribution of innovative laser-based medical devices and services. The company was originally founded in 1989 and is headquartered in Mountain View, California. IRIDEX's business model is divided into various divisions, each serving different markets. The divisions include ophthalmology, otolaryngology (ENT), gynecology and urology, as well as scientific research. The company offers a wide range of high-tech laser systems that can be used to treat various conditions, such as retinal diseases, glaucoma, nasal and throat disorders, gynecological and urological conditions, and other medical applications. One of the most well-known divisions of IRIDEX is ophthalmology, which offers a wide range of laser systems for the treatment of retinal diseases. These retinal diseases include diabetic retinopathy, retinal edema, age-related macular degeneration, and retinal detachment. The company also has a high-tech system called Cyclo G6TM, which is used for the treatment of glaucoma. This system can also be used in conjunction with other devices, such as ultrasound systems, for optimized clinical effectiveness. The ENT division offers laser systems for the treatment of nasal and throat disorders, such as snoring, polyps, stenosis, and tumors. The range of laser systems varies from simple systems to advanced systems that can be connected to a flexible endoscope for more precise treatment. IRIDEX's gynecology and urology division offers laser systems for various applications, such as urinary incontinence, bladder problems, tumor removal, prostate tissue removal, and medical treatments to improve sexual function. Laser systems can also be used in combination with other medical devices, such as ultrasound systems. The company places great emphasis on scientific research and development to create and introduce innovative technologies to the market. Therefore, IRIDEX collaborates closely with various research institutes, universities, and medical professionals to further develop its technological advances. The company is also committed to providing comprehensive training and support to its customers to ensure that they use the devices safely and effectively. Overall, IRIDEX Corp has established itself as an innovative and powerful multinational company in the field of medical technology. The company is constantly striving to expand its range of products and services and impress its customers with its high-quality solutions. IRIDEX is confident that it will continue to play a significant role in the medical technology industry in the future. IRIDEX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IRIDEX stock

Cash Conversion Rate (OCF/Net Income) of IRIDEX is 47.67 % in 2025.

Cash Conversion Rate (OCF/Net Income) of IRIDEX changed from 81.76 % to 47.67 %, representing a -41.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) IRIDEX since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s IRIDEX with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — IRIDEX

All Key Metrics — IRIDEX